Browse by all authors Browse By Author ID - Sheila Anne Doggrell

Browse Results (48 results found)

Subscribe to the RSS feed for this result setSubscribe to the RSS feed for this result set

Refine

  Abstract Views File Downloads Thomson Reuters Web of Science Citation Count Scopus Citation Count Altmetric Score
Doggrell, Sheila A. (2001) Alteplase: descendancy in myocardial infarction, ascendancy in stroke. Expert Opinion On Investigational Drugs, 10 11: 2013-2029. doi:10.1517/13543784.10.11.2013 98   2 Cited 4 times in Scopus4 0
Doggrell, Sheila A. (2001) Amiodarone - waxed and waned and waxed again. Expert Opinion on Pharmacotherapy, 2 11: 1877-1890. doi:10.1517/14656566.2.11.1877 74   Cited 23 times in Scopus23 0
Doggrell, Sheila A. (2002) Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease. Expert opinion on Pharmacotherapy, 3 11: 1543-1556. doi:10.1517/14656566.3.11.1543 63   Cited 11 times in Scopus11 0
Doggrell, Sheila A. (2005) A small-molecule lead compound for the treatment of Alzheimer's disease. Expert Opinion On Investigational Drugs, 14 2: 199-201. doi:10.1517/13543784.14.2.199 80   0 Cited 0 times in Scopus0 0
Doggrell, Sheils A. (2005) Berberine - a novel approach to cholesterol lowering. Expert Opinion On Investigational Drugs, 14 5: 683-685. doi:10.1517/13543784.14.5.683 87   25 Cited 28 times in Scopus28 1
Doggrell, Sheila A. (2005) BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia. Expert Opinion On Investigational Drugs, 14 1: 89-91. doi:10.1517/13543784.14.1.89 47   28 Cited 29 times in Scopus29 0
Doggrell, Sheila A. (2001) Brain natriuretic peptide: Disease marker or more in cardiovascular medicine?. Drugs of Today, 37 7: 463-476. doi:10.1358/dot.2001.37.7.844189 103   5 0
Doggrell, Sheila A. and Wanstall, Janet C. (2005) Cardiac chymase: pathophysiological role and therapeutic potential of chymase inhibitors. Canadian Journal of Physiology And Pharmacology, 83 2: 123-130. doi:10.1139/Y04-136 39   24 Cited 30 times in Scopus30 0
Doggrell, Sheila A. (2005) CHARMed - the effects of candesartan in heart failure. Expert Opinion On Pharmacotherapy, 6 3: 513-516. doi:10.1517/14656566.6.3.513 63   0 Cited 2 times in Scopus2 0
Brown, Lindsay. and Doggrell, Sheila A. (1999) Cholesterol, coronary artery disease, statins and consequences. New Zealand Pharmacy, 19 8: 25-27. 45  
Doggrell, Sheila A. (2002) Class benefits of AT1 antagonists in Type 2 diabetes with nephropathy. Expert opinion on Pharmacotheraphy, 3 5: 625-628. doi:10.1517/14656566.3.5.625 48   Cited 5 times in Scopus5 0
Doggrell, Sheila A. (2001) Clinical trials with glycoprotein IIB/IIIA antagonists - No benefit without bleeding?. Drugs of Today, 37 8: 509-531. doi:10.1358/dot.2001.37.8.844169 44   3 0
Doggrell, Sheila A. (2002) Clopidogrel: A CURE in acute coronary syndromes? (A Key Paper Evaluation). Exper Opinion in Pharmacotherapy, 3 3: 351-353. doi:10.1517/14656566.3.3.351 50   Cited 2 times in Scopus2 0
Doggrell, Sheila A. (2005) Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. Expert Opinion On Pharmacotherapy, 6 1: 75-84. doi:10.1517/14656566.6.1.75 221   23 Cited 31 times in Scopus31 0
Doggrell, Sheila A. and Brown, Lindsay (2000) D-Sotalol: death by the SWORD or deserving of further consideration for clinical use?. Expert Opinion On Investigational Drugs, 9 7: 1625-1634. doi:10.1517/13543784.9.7.1625 99   6 0
Doggrell, Sheila A. (2002) Effects of BDF 9198 on left ventricular contractility in advanced spontaneously hypertensive rats with heart failure. Journal of Pharmacy And Pharmacology, 54 8: 1097-1102. doi:10.1211/002235702320266253 40   0 Cited 0 times in Scopus0 0
Doggrell, Sheila A. and Nand, Vinita (2002) Effects of dofetilide on cardiovascular tissues from normo- and hypertensive rats. Journal of Pharmacy And Pharmacology, 54 5: 707-715. doi:10.1211/0022357021778862 36   0 Cited 1 times in Scopus1 0
Doggrell, Sheila A., Brown, Lindsay and Castaner, J (2002) EMD-57033. Treatment of heart failure, calcium sensitizer. Drugs of The Future, 27 1: 14-20. doi:10.1358/dof.2002.027.01.652651 49   1 Cited 2 times in Scopus2 0
Wanstall, Janet C., Homer, Kerry L. and Doggrell, Sheila A. (2005) Evidence for, and importance of, cGMP-Independent Mechanisms with NO and NO Donors and Blood Vessels and Platelets. Current and Vascular Pharmacology, 3 1: 41-53. doi:10.2174/1570161052773933 30   Cited 50 times in Scopus50 0
Doggrell, Sheila A. (2005) Farnesoid X receptor agonism - a new approach to the treatment of cholesterol gallstone disease. Expert Opinion On Investigational Drugs, 14 4: 535-538. doi:10.1517/13543784.14.4.535 42   1 Cited 1 times in Scopus1 0
Doggrell, Sheila A. (2002) Fondaparinux verses enoxaparin for the prevention of venous thromboembelism. Expert opinion on Pharmacotherapy, 3 4: 455-457. doi:10.1517/14656566.3.4.455 30   Cited 2 times in Scopus2 0
Doggrell, Sheila A. (2002) Functional beta(1)- and beta(2)-adrenoceptors in the left and right atrium of pre-hypertensive rats. Journal of Pharmacy And Pharmacology, 54 10: 1407-1412. doi:10.1211/002235702760345509 39   1 Cited 1 times in Scopus1 0
Doggrell, Sheila A., Wanstall, Janet C. and Gambino, Agatha (1999) Functional effects of 4-aminopyridine (4-AP) on pulmonary and systemic vessels from normoxic control and hypoxic pulmonary hypertensive rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 360 3: 317-323. doi:10.1007/s002109900064 42   15 Cited 15 times in Scopus15 0
Doggrell, Sheila A. (2005) Inhibitors of cholesteryl ester transfer protein - a step forward in the treatment of coronary artery disease?. Drugs of The Future, 30 1: 45-50. doi:10.1358/dof.2005.030.01.870718 56   0 Cited 1 times in Scopus1 0
Doggrell, Sheila A. (2001) Is bucindolol BEST? (A Key Paper Evaluation). Expert Opinion in Pharmacotherapy, 2 10: 1703-1705. doi:10.1517/14656566.2.10.1703 46   0
Doggrell, S., Field, C., Diwan, V. and Kairuz, T. (2012). Low adherence and understanding of medicines in the older-aged living in rental retirement villages. In: Proceedings of the National Medicines Symposium. National Medicines Symposium, Sydney, Australia, (). 24 - 25 May 2012. 22  
Doggrell, Sheila A. (2002) Metformin & lifestyle intervention prevent Type 2 diabetes: lifestyle intervention has the greater effect. Expert opinion on Pharmacotherapy, 3 7: 1011-1013. doi:10.1517/14656566.3.7.1011 50   Cited 9 times in Scopus9 0
Doggrell, Sheila A. (2005) NF-gamma B - a target in the inflammation of bone destruction. Expert Opinion On Therapeutic Targets, 9 1: 191-193. doi:10.1517/14728222.9.1.191 58   1 Cited 1 times in Scopus1 0
Doggrell, Sheila A., del Fresno, M. and Castaner, J. (2002) NPS-2143 - Treatment of osteoporosis - Calcilytic. Drugs of The Future, 27 2: 140-142. doi:10.1358/dof.2002.027.02.656406 87   4 Cited 4 times in Scopus4 0
Doggrell, Sheila A. (2001) Parathyroid hormone (1-34): A major advance in the treatment of osteoporosis?. Expert Opinion Pharmacotherapy, 2 11: 1919-1920. doi:10.1517/14656566.2.11.1919 39   0
Doggrell, Sheila A. (2001) Pharmacotherapy of intermittent claudication. Expert opinion on pharmacotherapy, 2 11: 1725-1736. doi:10.1517/14656566.2.11.1725 55   Cited 9 times in Scopus9 0
Doggrell, Sheila A. and Brown, Lindsay (2002) Present and future pharacotherapy for heart failure. Expert opinion on Pharacotherapy, 3 7: 915-930. doi:10.1517/14656566.3.7.915 43   Cited 19 times in Scopus19 0
Doggrell, Sheila A. (2002) Present and future pharmacotherapy for benign prostatic hyperplasia. Drugs of The Future, 27 10: 973-986. doi:10.1358/dof.2002.027.10.740186 58   5 Cited 8 times in Scopus8 0
Doggrell, Sheila A. (2001) ReoPro rules: results from the 'DoTirofiban and ReoPro give similar efficacy trial' (TARGET) - A Key Paper Evaluation (Topol, Ej et al). Expert Opinion in Pharmacotherapy, 2 9: 1507-1509. doi:10.1517/14656566.2.9.1507 40   Cited 2 times in Scopus2 0
Chen, Ying-Yu and Doggrell, Sheila A. (2002) Responsiveness, affinity constants and beta-adrenoceptor reserves for isoprenaline on aortae from normo-, pre and hypertensive rats. Journal of Pharmacy And Pharmacology, 54 4: 515-522. doi:10.1211/0022357021778790 36   4 Cited 5 times in Scopus5 0
Doggrell, Sheila A. (2002) TACE inhibition: a new approach to treating inflammation. Expert Opinion On Investigational Drugs, 11 7: 1003-1006. doi:10.1517/13543784.11.7.1003 25   26 Cited 26 times in Scopus26 0
Doggrell, Sheila A. (2001) Targets to trials in diabetic complications. Drugs of Today, 37 11: 739-748. doi:10.1358/dot.2001.37.11.844208 34   2 0
Brown, Lindsay., Hoong, Ian and Doggrell, Sheila A. (2000) The heart as a target for oestrogens. Heart, Lung and Circulation, 9 3: 113-125. doi:10.1046/j.1444-2892.2000.009003113.x 39   Cited 10 times in Scopus10 0
Doggrell, Sheila A. (2002) Therapeutic potential of selective superoxide dismutase mimetics. Drugs of The Future, 27 4: 385-390. doi:10.1358/dof.2002.027.04.664560 40   5 Cited 5 times in Scopus5 0
Doggrell, Sheila A. and Brown, Lindsay (2001) The spironolactone renaissance. Expert Opinion on Investigational Drugs, 10 5: 943-954. doi:10.1517/13543784.10.5.943 53   27 Cited 32 times in Scopus32 0
Doggrell, Sheila A. and Brown, Lindsay (2001) The spironolactone renaissance. Expert Opinion On Investigational Drugs, 10 5: 943-954. doi:10.1517/13543784.10.5.943 103   28 Cited 32 times in Scopus32 0
Doggrell, Sheila A. (2002) The therapeutic potential of dopamine modulators on the cardiovascular and renal systems. Expert Opinion On Investigational Drugs, 11 5: 631-644. doi:10.1517/13543784.11.5.631 37   7 Cited 11 times in Scopus11 0
Doggrell, Sheila A. (2002) The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system. Expert Opinion On Investigational Drugs, 11 11: 1537-1552. doi:10.1517/13543784.11.11.1537 36   9 Cited 11 times in Scopus11 0
Doggrell, Sheila A. and Evans, Suzanne (2003) Treatment of dementia with neurotransmission modulation. Expert Opinion On Investigational Drugs, 12 10: 1633-1654. doi:10.1517/13543784.12.10.1633 55   13 Cited 18 times in Scopus18 3
Doggrell, Sheila A. and Chan, Vincent W. (2001) Using models in cardiovascular research: report on the satellite meeting to the International Congress of Physiological Sciences, Models in Cardiovascular Research. Methods Find Experimental Clinical Pharmacology, 23 8: 457-464. 48  
Doggrell, Sheila A. (2005) Which drug combination for hormone-refractory prostate cancer. Expert Opinion On Pharmacotherapy, 6 4: 667-670. doi:10.1517/14656566.6.4.667 68   1 Cited 1 times in Scopus1 0
Doggrell, Sheila A. and Wanstall, Janet C. (2003) Will chymase inhibitors be the next major development for the treatment of cardiovascular disorders?. Expert Opinion On Investigational Drugs, 12 8: 1429-1432. doi:10.1517/13543784.12.8.1429 43   5 Cited 6 times in Scopus6 0
Doggrell, Sheila A. (2005) Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?. Expert Opinion On Investigational Drugs, 14 3: 339-342. doi:10.1517/13543784.14.3.339 66   7 Cited 13 times in Scopus13 0